These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15024551)

  • 1. In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.
    Slifstein M; Hwang DR; Huang Y; Guo N; Sudo Y; Narendran R; Talbot P; Laruelle M
    Psychopharmacology (Berl); 2004 Sep; 175(3):274-86. PubMed ID: 15024551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.
    Mukherjee J; Yang ZY; Brown T; Lew R; Wernick M; Ouyang X; Yasillo N; Chen CT; Mintzer R; Cooper M
    Nucl Med Biol; 1999 Jul; 26(5):519-27. PubMed ID: 10473190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
    Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
    Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol.
    Vandehey NT; Moirano JM; Converse AK; Holden JE; Mukherjee J; Murali D; Nickles RJ; Davidson RJ; Schneider ML; Christian BT
    J Cereb Blood Flow Metab; 2010 May; 30(5):994-1007. PubMed ID: 20040928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies.
    Slifstein M; Narendran R; Hwang DR; Sudo Y; Talbot PS; Huang Y; Laruelle M
    Synapse; 2004 Oct; 54(1):46-63. PubMed ID: 15300884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation of baseline dopamine D2 receptor occupancy in striatum and extrastriatal regions in humans with positron emission tomography with [18F] fallypride.
    Riccardi P; Baldwin R; Salomon R; Anderson S; Ansari MS; Li R; Dawant B; Bauernfeind A; Schmidt D; Kessler R
    Biol Psychiatry; 2008 Jan; 63(2):241-4. PubMed ID: 17586476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors.
    Mukherjee J; Christian BT; Dunigan KA; Shi B; Narayanan TK; Satter M; Mantil J
    Synapse; 2002 Dec; 46(3):170-88. PubMed ID: 12325044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans.
    Cropley VL; Innis RB; Nathan PJ; Brown AK; Sangare JL; Lerner A; Ryu YH; Sprague KE; Pike VW; Fujita M
    Synapse; 2008 Jun; 62(6):399-408. PubMed ID: 18361438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of 5-[18F]fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors.
    Kessler RM; Votaw JR; de Paulis T; Bingham DR; Ansari MS; Mason NS; Holburn G; Schmidt DE; Votaw DB; Manning RG
    Synapse; 1993 Nov; 15(3):169-76. PubMed ID: 8278895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities.
    Siessmeier T; Zhou Y; Buchholz HG; Landvogt C; Vernaleken I; Piel M; Schirrmacher R; Rösch F; Schreckenberger M; Wong DF; Cumming P; Gründer G; Bartenstein P
    J Nucl Med; 2005 Jun; 46(6):964-72. PubMed ID: 15937307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol.
    Christian BT; Narayanan T; Shi B; Morris ED; Mantil J; Mukherjee J
    J Cereb Blood Flow Metab; 2004 Mar; 24(3):309-22. PubMed ID: 15091112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.
    Rominger A; Cumming P; Xiong G; Koller G; Böning G; Wulff M; Zwergal A; Förster S; Reilhac A; Munk O; Soyka M; Wängler B; Bartenstein P; la Fougère C; Pogarell O
    Addict Biol; 2012 Mar; 17(2):490-503. PubMed ID: 22023291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amphetamine-induced displacement of [18F] fallypride in striatum and extrastriatal regions in humans.
    Riccardi P; Li R; Ansari MS; Zald D; Park S; Dawant B; Anderson S; Doop M; Woodward N; Schoenberg E; Schmidt D; Baldwin R; Kessler R
    Neuropsychopharmacology; 2006 May; 31(5):1016-26. PubMed ID: 16237395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized in vivo detection of dopamine release using 18F-fallypride PET.
    Ceccarini J; Vrieze E; Koole M; Muylle T; Bormans G; Claes S; Van Laere K
    J Nucl Med; 2012 Oct; 53(10):1565-72. PubMed ID: 22933820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallypride.
    Constantinescu CC; Coleman RA; Pan ML; Mukherjee J
    Synapse; 2011 Aug; 65(8):778-87. PubMed ID: 21218455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET.
    Mukherjee J; Christian BT; Narayanan TK; Shi B; Collins D
    Brain Res; 2005 Jan; 1032(1-2):77-84. PubMed ID: 15680944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
    Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.
    de Paulis T
    Curr Pharm Des; 2003; 9(8):673-96. PubMed ID: 12570798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.